Navigation Links
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
Date:7/2/2008

e a possible basis for treatment stratification to LOR-2040 and high dose cytarabine combination.

Favorable disease responses included complete responses in 35% of the 23 patients and significant cytoreduction of leukemic blasts in two others. As a further favourable outcome, these two patients and five of the patients who had complete responses were able to progress to a successful transplant, a desired outcome of successful salvage therapy. Notably, the study population included unfavourable patients with at least one adverse prognostic characteristic.

The clinical study also measured intracellular uptake of LOR-2040 in the bone marrow leukemic cells, and identified significant accumulation of the drug in the bone marrow blast cells and suggested preferential uptake of the drug by CD34+ cells, an important malignant bone marrow cell population.

The authors concluded that LOR-2040 in combination with high dose cytarabine is feasible, is active against its target R2, and "holds promise in younger patients with refractory or relapsed AML". The tolerability profile of this combination regimen was assessed as similar to that expected from high dose cytarabine alone.

"This successful clinical study has provided a detailed supporting rationale for our ongoing development program with LOR-2040 in AML", said Dr Aiping Young, Lorus' President and CEO. "This study supports Lorus' view that a highly specific targeted therapy approach can achieve efficacy with minimal impact on toxicity".

A Phase II program with LOR-2040 in this combination is presently ongoing to extend and confirm these findings in patients with refractory or relapsed AML.

About LOR-2040

LOR-2040 (formerly GTI-2040) is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, LOR-2040 has demonstrated strong antitumor and antimetastatic act
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... CHAPEL HILL, N.C., Aug. 22 Quality and ... year in light of,demands for higher efficiencies fueled ... issues on multiple fronts --,smaller pipelines are affecting ... increasing and harsher FDA regulations brought more scrutiny ...
... non-profit, faith-based and community organizations to ... proactively get the job done, ... agreement with a non-profit organization to utilize its,Ogiene(TM) FE technology to ... safely used by those families so desperately in need,of biohazard-free housing., ...
... Cellular Platform Utilizing Cord, Blood and Menstrual Blood Derived Stem ... ... Vascular Structures, OLDSMAR, Fla., Aug. 21 Cryo-Cell,International, ... research collaboration to co-develop a combined cellular,platform therapeutic for rapidly ...
Cached Biology Technology:Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 2Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 3Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 4
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... method to identify DNA mutations may shepherd in an ... screening and identification of genes that harbor disease. , ... Biosensors at the Biodesign Institute at ASU, led a ... of biosensors, electronics, and nanotechnology to fashion nanocrystals that ...
... provide for study of human immune responses, scientists have ... rapid immune response by two separate armies of defensive ... microbes like the leprosy bug, this initial defense sometimes ... yields to a dangerous, spreading infection. , Led by ...
... University of North Carolina at Chapel Hill is one ... the National Institutes of Health to study why good ... the next seven years, the Drug-Induced Liver Injury Network, ... liver injury caused by prescription and over-the-counter medications, nutritional ...
Cached Biology News:Bioelectronic ‘signatures?hold key to DNA mutations 2Leprosy microbes lead scientists to immune discovery 2UNC launches study of liver injury caused by drugs 2
... Sheep polyclonal to Decorin ( Abpromise ... Antigen: Synthetic peptide: ... amino acids 6-19 of Human Decorin ... bone proteoglycan II). ...
...
... NEW VSOS-4P, all Programmable and Digital Orbital Shaker. ... been redesigned to make every day use even ... memory for up to 4 different programs. Its ... your program. Furthermore, the VSOS-4P has a pulse ...
... plus,for Reliable Sterile Filtration of Tissue Culture ... pump or tube pump, quickly and,reliably sterilize ... aqueous solutions. The combination of a ... de-aeration,ensures high flow rates and optimal total,throughputs. ...
Biology Products: